Evidence map›Paper›PMID 36930339›Full record

SynthesisSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2023

Prophylactic gabapentin during head and neck cancer therapy: a systematic review and meta-analysis.

Loren E Smith, Barbara A Murphy, Derek K Smith

Open access · hybridFull text readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Loren E SmithDepartment of Anesthesiology, Vanderbilt University Medical Center, Nashville, TN, USA.
Barbara A MurphyDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Derek K SmithAmerican Dental Association Science and Research Institute, Chicago, IL, USA. smithd@ada.org.
Vanderbilt University Medical Center · USAmerican Dental Association · US

Funding

Perioperative high-density lipoproteins and postoperative AKIK23GM134482 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI SMITH, LOREN ELISA · 2020 to 2024
$933k
Developing an oral health screening tool for an integrated model of care to reduce treatment-related oral morbidity in head and neck cancer survivorK23DE028010 · NIDCR · VANDERBILT UNIVERSITY MEDICAL CENTER · PI SMITH, DEREK KYLE · 2019 to 2023
$632k
NIDCR NIH HHS K23 DE028010NIGMS NIH HHS K23 GM134482NIH HHS K23DE028010NIH HHS K23GM134482
6 · The paper itself

Abstract

purposeThis review was designed to compile the currently available evidence on the prophylactic use of gabapentin in the head and neck cancer patient population.

methodsA systematic search was conducted of PubMed, Web of Science, and Google Scholar to identify articles related to the use of prophylactic gabapentin in patients undergoing head and neck cancer therapy. Candidate studies were screened for inclusion and a subsequent bias assessment was conducted by multiple reviewers. Meta-analysis was conducted in cases in which the studies used compatible outcome measures.

resultsTen studies were identified that met the inclusion criteria and were assessed for bias. Among the four small studies that examined pain prevention, 2 were positive and 2 were inconclusive. Three of the four studies examiniRDng opioid use noted less need for opioids in the treatment arm. Meta-analysis of the pertinent studies showed no difference in feeding tube placement (RD = 0.64%, 95%CI: (- 25.8%, 27.1%), p = 0.962) but substantially less weight loss among those in the treatment arm (p = 0.047).

conclusionProphylactic gabapentin appears to be a promising treatment option for preventing pain, reducing opioids, and reducing weight loss in patients undergoing head and neck cancer therapy. However, the studies on the treatment to date are small and several have a substantial risk of bias.

Indexed as

Cyclohexanecarboxylic AcidsHead and Neck NeoplasmsAminesAnalgesicsAnalgesics, OpioidGabapentingamma-Aminobutyric AcidHumansPainWeight LossAminesAnalgesicsAnalgesics, OpioidCyclohexanecarboxylic AcidsGabapentingamma-Aminobutyric AcidGabapentinHead and neck cancerMeta-analysisOpioidsSystematic review

Identifiers

PMID36930339
PMCPMC10023599
OpenAlexW4327680680

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read58
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.